26
Participants
Start Date
June 14, 2017
Primary Completion Date
March 31, 2019
Study Completion Date
December 31, 2022
Pomalidomide 2 MG Oral Capsule [Pomalyst]
Pomalidomide is an oral immunomodulatory derivative of thalidomide. Thalidomide and its derivatives are small molecules with broad effects on immune activation, including T-cell activation and responsiveness. Pomalidomide augments T cell responsiveness and proliferation by several mechanisms, many mediated by transcriptional regulation downstream of its primary target, cereblon. Effects include increased production of IL-2 and interferon-γ (IFN-γ), enhanced CD4+ and CD8+ T cell co-stimulation.
St Vincent's Hospital, Darlinghurst
Lead Sponsor
Kirby Institute
OTHER_GOV